Handelsbanken Fonder AB Purchases 21,990 Shares of Zoetis Inc. $ZTS

Handelsbanken Fonder AB grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 10.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,467 shares of the company’s stock after purchasing an additional 21,990 shares during the period. Handelsbanken Fonder AB owned approximately 0.05% of Zoetis worth $16,418,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ZTS. Prosperity Bancshares Inc purchased a new stake in shares of Zoetis during the 4th quarter valued at $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis during the 1st quarter valued at about $28,000. Root Financial Partners LLC increased its stake in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the period. Elyxium Wealth LLC purchased a new position in shares of Zoetis in the fourth quarter valued at about $32,000. Finally, Wellington Grp LLC raised its position in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ZTS. TD Cowen decreased their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Piper Sandler decreased their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday. UBS Group dropped their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Finally, Barclays cut their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $109.62.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Citigroup maintained a “buy” rating despite lowering its price target from $112 to $96, while BNP Paribas Exane maintained an “outperform” rating and reduced its target from $146 to $110. Both targets imply substantial upside from current levels. Citigroup and BNP Paribas Exane price target updates
• Positive Sentiment: Recent analyst coverage remains mixed rather than uniformly bearish: HSBC issued a “buy” rating, and the median price target from seven analysts is $99. Zoetis also reported quarterly earnings slightly above consensus and has recently attracted purchases from some institutional investors and company insiders.
• Neutral Sentiment: The broader analyst consensus is “hold,” reflecting uncertainty over the pace of recovery. Zacks Research separately downgraded the stock from “hold” to “strong sell,” highlighting the increasingly divided view on Zoetis’ near-term prospects. Zacks Research rating update
• Negative Sentiment: Investors remain concerned about softer U.S. companion-animal demand, including fewer veterinary visits, greater price sensitivity among pet owners and heavier competition in dermatology and parasiticides. These pressures have affected key brands and contributed to weaker sales trends. Zoetis pet-care demand and competitive pressure analysis
• Negative Sentiment: Zoetis reduced its 2026 revenue-growth and adjusted-earnings outlook in May. The market is still digesting the lower expectations, while recent target cuts from Piper Sandler, Citigroup and BNP Paribas Exane have reinforced concerns that a recovery may take longer than expected. Piper Sandler forecast for Zoetis
• Negative Sentiment: The stock recently reached a new 52-week low after an analyst downgrade, intensifying technical and sentiment pressure. Although quarterly EPS exceeded estimates, revenue fell slightly year over year and missed consensus, limiting the positive impact of the earnings beat. Zoetis 52-week low report

Zoetis Stock Performance

NYSE:ZTS opened at $73.47 on Thursday. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock has a 50-day simple moving average of $76.49 and a two-hundred day simple moving average of $99.53. The firm has a market capitalization of $30.36 billion, a PE ratio of 12.10, a P/E/G ratio of 1.30 and a beta of 0.74. Zoetis Inc. has a 52-week low of $71.45 and a 52-week high of $160.48.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s quarterly revenue was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts forecast that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s payout ratio is currently 34.93%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.